A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Trial ID or NCT#
NCT00959647
Status
NOT RECRUITING
Purpose
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.
Official Title
An Open-label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Completed vismodegib treatment within 2-4 weeks in a Genentech-sponsored parent study or continued to receive vismodegib at the time the Genentech-sponsored parent study closed. - Expectation by the investigator that the participant may continue to benefit from additional vismodegib treatment.
Exclusion Criteria:
- - Intervening anti-tumor therapy not specified in the parent study (ie, non-protocol-specified chemotherapy, other targeted therapy, radiation therapy, or photodynamic therapy).
Investigator(s)
Anthony Oro, MD, PhD
Hair loss specialist,
Dermatologic oncologist,
Cutaneous oncology specialist,
Skin stem cell specialist
Eugene and Gloria Bauer Professor
Bernice Kwong, MD
Dermatologist,
Dermatologic oncologist,
Cutaneous oncology specialist,
Dermato-oncology specialist,
Dermatopathologist
Clinical Professor, Dermatology
Anne Lynn S. Chang, MD
Dermatologist,
General dermatologist,
Dermatologic oncologist,
Cutaneous oncology specialist
Professor of Dermatology
A. Dimitrios Colevas, MD
Medical oncologist,
Head and neck specialist,
Cutaneous oncology specialist
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Contact us to find out if this trial is right for you.
Contact
Cancer Clinical Trials Office
650-498-7061
View on ClinicalTrials.gov
